<p>Adicet Bio, Inc.（納斯達克代碼：ACET - 免費報告）的股票計劃於 12 月 30 日（星期二）進行反向拆分。最近宣佈的反向拆分比例為 1 比 16。股東所持股份的數量將在 12 月 29 日（星期一）收盤後進行調整。</p>
<h2>Adicet Bio 股票表現</h2>
<p>在週五的午盤交易中，納斯達克 ACET 的股票上漲了 $0.00，達到了 $0.52。該公司交易了 2,937,097 股股票，而其平均交易量為 1,112,400 股。該公司的 50 日移動平均價格為 $0.64，200 日移動平均價格為 $0.71。公司的債務與股本比率為 0.01，流動比率為 5.62，速動比率為 5.62。該公司的市值為 7970 萬美元，市盈率為 -0.41，貝塔值為 1.61。Adicet Bio 的 52 周低點為 $0.45，52 周高點為 $1.11。</p>
<p>Adicet Bio（納斯達克代碼：ACET - 獲取免費報告）最近於 11 月 5 日（星期三）發佈了季度財報。公司報告本季度每股收益（EPS）為（$0.29），低於分析師一致預期的（$0.26），差距為（$0.03）。分析師預測，Adicet Bio 本年度將發佈 -1.39 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>多家研究公司最近對 ACET 發表了看法。花旗集團在 11 月 19 日（星期三）的研究報告中重申了對 Adicet Bio 股票的 “市場表現” 評級。傑富瑞金融集團在 10 月 7 日（星期二）的研究報告中將 Adicet Bio 股票的評級提升至 “強力買入”。Wedbush 在 11 月 6 日（星期四）的研究報告中重申了 “跑贏大盤” 的評級，並對 Adicet Bio 股票設定了 $5.00 的目標價。Weiss Ratings 在 10 月 30 日（星期四）的研究報告中重申了對 Adicet Bio 股票的 “賣出（d-）” 評級。最後，古根海姆在 10 月 8 日（星期三）的研究報告中將 Adicet Bio 股票的目標價從 $7.00 提升至 $8.00，並給予該股票 “買入” 評級。一位股票研究分析師給予該股票 “強力買入” 評級，三位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Adicet Bio 目前的平均評級為 “適度買入”，共識目標價為 $7.33。</p>
<p><strong>獲取我們對 Adicet Bio 的最新分析</strong></p>
<h2>機構投資者對 Adicet Bio 的看法</h2>
<p>多家機構投資者最近對 ACET 的持倉進行了調整。Susquehanna International Group LLP 在第三季度新購入了 Adicet Bio 的股份，價值 $33,000。Citadel Advisors LLC 在第三季度將其在 Adicet Bio 股票中的持股比例提高了 19.8%。Citadel Advisors LLC 目前持有 583,948 股該公司的股票，價值 $473,000，此前在該期間內又購買了 96,342 股。Virtu Financial LLC 在第三季度新購入了 Adicet Bio 的股份，價值約 $65,000。Two Sigma Investments LP 在第三季度將其在 Adicet Bio 股票中的持倉增加了 66.6%。Two Sigma Investments LP 目前持有 854,568 股該公司的股票，價值 $692,000，此前在上個季度又購買了 341,761 股。最後，Squarepoint Ops LLC 在第三季度新購入了 Adicet Bio 的股份，價值約 $38,000。目前 83.89% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Adicet Bio</h2>
<p>（獲取免費報告）</p>
<p>Adicet Bio, Inc.（納斯達克：ACET）是一家臨牀階段的生物技術公司，專注於開發現成的、同種異體的伽馬δ（γδ）T 細胞療法，用於腫瘤和自身免疫疾病。該公司的專有平台使得能夠對γδ T 細胞進行基因工程改造，結合嵌合抗原受體（CARs）和其他分子修飾，以增強腫瘤靶向、擴展和持久性。通過利用γδ T 細胞的固有腫瘤識別特性，Adicet 旨在克服與自體細胞療法相關的製造和安全挑戰。</p>
<p>Adicet 的主要產品候選藥物 ADI-001 是一種針對 CD20 的 CAR 工程化同種異體 γδ T 細胞療法，用於治療復發或難治性 B 細胞惡性腫瘤。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Adicet Bio</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>開火正式開始……</li>
<li>華盛頓準備開戰</li>
<li>你的 “出生權索賠” 剛剛被激活</li>
<li>在 1 月 1 日之前將 $1,000 投入這隻股票 [不是 NVDA]</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 $1,000 到 Adicet Bio 嗎？</h2>
<p>在你考慮 Adicet Bio 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Adicet Bio 並不在名單上。</p>
<p>雖然 Adicet Bio 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ACET

<p>Adicet Bio, Inc.（納斯達克代碼：ACET）將於 12 月 30 日進行 1 比 16 的反向拆股。股東的持股將在 12 月 29 日市場收盤後進行調整。該公司的股票表現顯示當前價格為 0.52 美元，市值為 7970 萬美元。分析師對該股票的評級不一，普遍目標價為 7.33 美元。機構投資者持有該股票的 83.89%。Adicet Bio 專注於開發用於腫瘤和自身免疫疾病的異體伽馬δ T 細胞療法</p>

<p>Shares of Adicet Bio, Inc. (NASDAQ:ACET - Free Report) are scheduled to reverse split on Tuesday, December 30th. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 29th.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.（納斯達克代碼：ACET - 免費報告）的股票計劃於 12 月 30 日（星期二）進行反向拆分。最近宣佈的反向拆分比例為 1 比 16。股東所持股份的數量將在 12 月 29 日（星期一）收盤後進行調整。</p>
</div><h2>Adicet Bio Stock Performance</h2>
<div class="lb-trans"><h2>Adicet Bio 股票表現</h2>
</div><p>Shares of NASDAQ ACET traded up $0.00 during mid-day trading on Friday, reaching $0.52. 2,937,097 shares of the company's stock were exchanged, compared to its average volume of 1,112,400. The firm has a 50-day moving average price of $0.64 and a two-hundred day moving average price of $0.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.62 and a quick ratio of 5.62. The firm has a market capitalization of $79.70 million, a price-to-earnings ratio of -0.41 and a beta of 1.61. Adicet Bio has a 52 week low of $0.45 and a 52 week high of $1.11.</p>
<div class="lb-trans"><p>在週五的午盤交易中，納斯達克 ACET 的股票上漲了 $0.00，達到了 $0.52。該公司交易了 2,937,097 股股票，而其平均交易量為 1,112,400 股。該公司的 50 日移動平均價格為 $0.64，200 日移動平均價格為 $0.71。公司的債務與股本比率為 0.01，流動比率為 5.62，速動比率為 5.62。該公司的市值為 7970 萬美元，市盈率為 -0.41，貝塔值為 1.61。Adicet Bio 的 52 周低點為 $0.45，52 周高點為 $1.11。</p>
</div><p>Adicet Bio (NASDAQ:ACET - Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.03). Analysts predict that Adicet Bio will post -1.39 EPS for the current year.</p>
<div class="lb-trans"><p>Adicet Bio（納斯達克代碼：ACET - 獲取免費報告）最近於 11 月 5 日（星期三）發佈了季度財報。公司報告本季度每股收益（EPS）為（$0.29），低於分析師一致預期的（$0.26），差距為（$0.03）。分析師預測，Adicet Bio 本年度將發佈 -1.39 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research firms have recently weighed in on ACET. Citigroup reissued a &#34;market perform&#34; rating on shares of Adicet Bio in a research note on Wednesday, November 19th. Jefferies Financial Group raised shares of Adicet Bio to a &#34;strong-buy&#34; rating in a research note on Tuesday, October 7th. Wedbush reaffirmed an &#34;outperform&#34; rating and issued a $5.00 price target on shares of Adicet Bio in a research note on Thursday, November 6th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adicet Bio in a research note on Thursday, October 30th. Finally, Guggenheim boosted their price objective on shares of Adicet Bio from $7.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Adicet Bio presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $7.33.</p>
<div class="lb-trans"><p>多家研究公司最近對 ACET 發表了看法。花旗集團在 11 月 19 日（星期三）的研究報告中重申了對 Adicet Bio 股票的 “市場表現” 評級。傑富瑞金融集團在 10 月 7 日（星期二）的研究報告中將 Adicet Bio 股票的評級提升至 “強力買入”。Wedbush 在 11 月 6 日（星期四）的研究報告中重申了 “跑贏大盤” 的評級，並對 Adicet Bio 股票設定了 $5.00 的目標價。Weiss Ratings 在 10 月 30 日（星期四）的研究報告中重申了對 Adicet Bio 股票的 “賣出（d-）” 評級。最後，古根海姆在 10 月 8 日（星期三）的研究報告中將 Adicet Bio 股票的目標價從 $7.00 提升至 $8.00，並給予該股票 “買入” 評級。一位股票研究分析師給予該股票 “強力買入” 評級，三位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Adicet Bio 目前的平均評級為 “適度買入”，共識目標價為 $7.33。</p>
</div><p><strong>Get Our Latest Analysis on Adicet Bio</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Adicet Bio 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Adicet Bio</h2>
<div class="lb-trans"><h2>機構投資者對 Adicet Bio 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in ACET. Susquehanna International Group LLP acquired a new position in Adicet Bio during the 3rd quarter worth $33,000. Citadel Advisors LLC boosted its stake in shares of Adicet Bio by 19.8% in the 3rd quarter. Citadel Advisors LLC now owns 583,948 shares of the company's stock valued at $473,000 after buying an additional 96,342 shares during the period. Virtu Financial LLC acquired a new position in shares of Adicet Bio during the third quarter worth about $65,000. Two Sigma Investments LP grew its position in shares of Adicet Bio by 66.6% during the third quarter. Two Sigma Investments LP now owns 854,568 shares of the company's stock worth $692,000 after buying an additional 341,761 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of Adicet Bio during the third quarter worth approximately $38,000. 83.89% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>多家機構投資者最近對 ACET 的持倉進行了調整。Susquehanna International Group LLP 在第三季度新購入了 Adicet Bio 的股份，價值 $33,000。Citadel Advisors LLC 在第三季度將其在 Adicet Bio 股票中的持股比例提高了 19.8%。Citadel Advisors LLC 目前持有 583,948 股該公司的股票，價值 $473,000，此前在該期間內又購買了 96,342 股。Virtu Financial LLC 在第三季度新購入了 Adicet Bio 的股份，價值約 $65,000。Two Sigma Investments LP 在第三季度將其在 Adicet Bio 股票中的持倉增加了 66.6%。Two Sigma Investments LP 目前持有 854,568 股該公司的股票，價值 $692,000，此前在上個季度又購買了 341,761 股。最後，Squarepoint Ops LLC 在第三季度新購入了 Adicet Bio 的股份，價值約 $38,000。目前 83.89% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Adicet Bio</h2>
<div class="lb-trans"><h2>關於 Adicet Bio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Adicet Bio, Inc NASDAQ: ACET is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company's proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.</p>
<div class="lb-trans"><p>Adicet Bio, Inc.（納斯達克：ACET）是一家臨牀階段的生物技術公司，專注於開發現成的、同種異體的伽馬δ（γδ）T 細胞療法，用於腫瘤和自身免疫疾病。該公司的專有平台使得能夠對γδ T 細胞進行基因工程改造，結合嵌合抗原受體（CARs）和其他分子修飾，以增強腫瘤靶向、擴展和持久性。通過利用γδ T 細胞的固有腫瘤識別特性，Adicet 旨在克服與自體細胞療法相關的製造和安全挑戰。</p>
</div><p>Adicet's lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.</p>
<div class="lb-trans"><p>Adicet 的主要產品候選藥物 ADI-001 是一種針對 CD20 的 CAR 工程化同種異體 γδ T 細胞療法，用於治療復發或難治性 B 細胞惡性腫瘤。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Adicet Bio</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Shots officially fired…</li>
<li>Washington prepares for war</li>
<li>Your “birthright claim” just got activated</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Adicet Bio</li>
<li>你知道亞馬遜計劃在 1 月 1 日做什麼嗎？</li>
<li>開火正式開始……</li>
<li>華盛頓準備開戰</li>
<li>你的 “出生權索賠” 剛剛被激活</li>
<li>在 1 月 1 日之前將 $1,000 投入這隻股票 [不是 NVDA]</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adicet Bio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 到 Adicet Bio 嗎？</h2>
</div><p>Before you consider Adicet Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Adicet Bio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Adicet Bio 並不在名單上。</p>
</div><p>While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adicet Bio 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Adicet Bio 股票計劃於 12 月 30 日星期二進行反向拆股（NASDAQ:ACET）